What were the specific outcomes of the virtual Capital Markets Day for izicopan, planned for spring 2026, as announced on January 8, 2026?

InflaRx N.V. (Nasdaq: IFRX) announced on January 8, 2026, its intention to host a virtual Capital Markets Day in Spring 2026. The purpose of this event was to highlight the clinical utility and commercial potential of its leading pipeline asset, izicopan, particularly in hidradenitis suppurativa (HS) and inflammation and immunology (I&I) broadly.1

As of April 16, 2026, which falls within the Spring 2026 timeframe, specific outcomes or a summary of this virtual Capital Markets Day have not been publicly disclosed in the available information. The announcement primarily outlined the company's strategic focus on izicopan, including progressing towards Phase 2b readiness in HS, conducting a PK bridging study in China in 2026 to enable expedited proof-of-concept studies, and fostering discussions with potential collaborators.1 InflaRx also noted a workforce reduction of approximately 30% to extend its cash runway to mid-2027.1